Abstract: The invention concerns a method for the determination of an analyte in which rheumatoid factors or rheumatoid-factor-like substances are added as an interference reducing reagent to reduce of avoid a hook effect. The invention in addition concerns suitable reagent kits for carrying out the method.

Abstract: Method for sequencing a nucleic acid molecule in a thermocycling reaction which initially comprises a nucleic acid molecule, a first primer, a second primer, a reaction buffer, a first thermostable DNA polymerase, (optionally) a thermostable pyrophosphatase, deoxynucleotides or derivatives thereof and a dideoxynucleotide or a derivative thereof and which is characterized in that the thermocycling reaction additionally contains a second thermostable DNA polymerase which, in comparison to the said first thermostable DNA polymerase, has a reduced ability to incorporate dideoxynucleotides as well as the use of the said method.

Abstract: The present invention concerns a method for the detection of nucleic acids on an analytical element which contains a sample application zone and a detection zone, the analytical element enabling liquid transport from the sample application zone to the detection zone, wherein a sample is applied to the sample application zone of the analytical element and the nucleic acids contained in the sample are denatured and can be detected qualitatively in the detection zone by hybridization with a detection probe and also quantitatively, preferably by means of marker groups. In addition new analytical elements and reagent kits for the detection of nucleic acids are provided.

Abstract: A method and a device for removing an analytic consumable product, in particular a test element, from a storage container having chambers which are sealed by foils from which the consumable product is pushed out by means of a plunger (7) can be optimized in that the magnitude of the thrusting force exercised by the plunger (7) during its forward motion can be controlled in dependence on the plunger (7) position.

Abstract: A polypeptide with the properties of collagenase class I from Clostridium histolyticum (CHC I) and the amino acid sequence SEQ ID NO:2 which is optionally N-terminally extended by one or several amino acids of the sequence SEQ ID NO:3 is advantageously suitable for the isolation of cells from mammalian tissue and human tissue.

Abstract: A titer of retroviral vectors of at least about 107 colony-forming units/ml cell culture supernatants is obtained using an amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes.

Abstract: The invention relates to use of diphosphonic acids or physiologically compatible salts or esters thereof for preventive treatment of disturbances to ossary mineralization which may occur after operative extension of the urine bladder by augmentation plasties or replacement of the urine bladder by replacement plasties but often do not appear until years after the operation.

Abstract: Compounds of formula I, useful as matrix metalloprotease inhibitors, wherein X, Y and Z are each oxygen; R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen; R2 and R3 are each hydrogen; and R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C1-C6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, —

Abstract: The invention concerns a process for coating a metallic or semimetallic surface in which coating molecules containing reactive groups are bound covalently to the surface by irradiation with light and it also concerns a structured coated surface.

Abstract: A process for producing erythropoietin which is free of foreign animal proteins except for the proteins of the host cell, wherein DNA coding for EPO is expressed in a eukaryotic host cell and the host cell is cultured in a medium free of natural mammalian proteins. The erythropoietin is chromatographically purified using dye affinity chromatography, chromatography on hydroxyapatite, reversed phase chromatography, and anion exchange chromatography. The resulting preparation contains less than 100 ppm of proteins derived from the host cell, and less than 10 pg of host cell DNA per 83 &mgr;g erythropoietin.

Abstract: A skeleton-free functional layer of high precision which contains a wetting agent of formula I, II and/or III R1—CO—N(R2)—CH2—COOMe  (I) R1—CO—N(R2)—CH2—CH2—SO3Me  (II) HO2C—CH2—CH2—CH(NH—COR1)—CO2Me  (III) in which R1 is a long-chained aliphatic residue, R2 is an alkyl residue with 1 to 8 C atoms and Me represents hydrogen or a metal atom, a diagnostic test strip having this functional layer as well as processes for the production of these objects are described.

Abstract: The combination of two mechanisms of detection in a single device yields a method which allows the simple quantification of analyte determinations. Suitable formats and reagent kits are suggested.

Abstract: The invention concerns a method for typing antibodies in a sample liquid by means of type-specific antigens and in particular a method for typing antibodies to the hepatitis C virus and peptide antigens suitable for this.

Abstract: The invention concerns a process for the production of muteins of eukaryotic polypeptides in eukaryotic cells by means of homologous recombination. The invention additionally concerns a process for the production of human cells which are suitable for the production of human mutated proteins. Finally the invention concerns the human cells produced by the process and mutated human proteins obtainable therefrom as well as pharmaceutical preparations which contain these muteins.

Abstract: Improved process of compounds of formula III in which A denotes CH═CH or S W denotes O X denotes S, O or NR2 in which the residue R2 is hydrogen or C1-C6 alkyl, Y denotes CH or N R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine, R1 denotes hydrogen or C1-C6 alkyl and n denotes 1-3 by reducing a compound of the general formula IV, in which A, W, X, Y, R, R1 and n have the meanings stated above with activated aluminum in a protic solvent, as well as new compounds of formula III and pharmaceutical preparations containing these compounds.

Abstract: The present invention provides a pharmaceutical combination preparation comprising an erythropoietin preparation that provides active erythropoietin and at least one modified haemoglobin wherein the erythropoietin preparation and modified haemoglobin can be present in separate forms of administration or in a single form of administration. The pharmaceutical combination preparations of the present invention can be used to treat manifest anemias with or without iron utilization disorders.

Abstract: A hypodermic needleless injection system for injecting a liquid medication, which system comprises: a medication unit configured and dimensioned to store a volume of liquid to be injected, the medication unit having a first region and a second region that are in liquid communication with each other, the first region being deformable and the second region having at least one orifice, a hydrostatic chamber containing a hydrostatic pressure transfer medium, the hydrostatic chamber being so configured and dimensioned that the medication unit is located at least partially within the hydrostatic chamber and so that a pressure exerted on the transfer medium would cause the first region of the medication unit to deform so as to reduce the volume available for the liquid medication within the medication unit, and a first piston having a first end and a second end opposite to the first end, the first end having a surface which forms a closure of the hydrostatic chamber, and is adapted for applying a pressure on the tra

Abstract: A pill dispenser allows for alternating removal of two or more solid forms of pharmaceutical medications, such as tablets, film tablets, coated tablets, or capsules. The pill dispenser has a housing, a baseplate, at least two storage containers for receiving and storing a solid form of medication, and a dosing slide. The baseplate is attached to the bottom end of the housing and has at least one ejecting opening. The storage containers are adapted for receiving and storing solid forms of medications. Each storage container has a bottom opening. A dosing slide is movably mounted between the storage containers and the baseplate and has receiving openings arranged in the dosing slide so that each of the receiving openings can be positioned under a bottom opening of a storage container and above an ejecting opening.

Abstract: The present invention concerns a method for determining and monitoring tissue glucose concentration. Additionally, the present invention concerns a measuring apparatus to determine and monitor glucose concentration.

Abstract: The invention concerns the stabilization and amplification of electrochemiluminescence signals in detection methods.